236 related articles for article (PubMed ID: 17263130)
1. Stem cell transplant for first relapse from the multiple myeloma research foundation.
Anderson KC; Vesole DH
Oncology (Williston Park); 2006 Dec; 20(14):1818, 1820-1, 1825-6. PubMed ID: 17263130
[TBL] [Abstract][Full Text] [Related]
2. New strategies in transplantation therapy.
Harousseau JL
Oncology (Williston Park); 2004 Nov; 18(13):1614-5, 1617. PubMed ID: 15648294
[TBL] [Abstract][Full Text] [Related]
3. Treatment options for older myeloma patients. From the Multiple Myeloma Research Foundation.
Anderson KC; Palumbo A;
Oncology (Williston Park); 2005 Apr; 19(4):447-50. PubMed ID: 15934516
[TBL] [Abstract][Full Text] [Related]
4. Myeloma bone disease: pathogenesis and treatment.
Roodman GD;
Oncology (Williston Park); 2005 Jul; 19(8):983-4, 986. PubMed ID: 16131042
[TBL] [Abstract][Full Text] [Related]
5. Prognostic indicators for the diagnosis of multiple myeloma.
Greipp P;
Oncology (Williston Park); 2004 May; 18(5):558-60. PubMed ID: 15209186
[TBL] [Abstract][Full Text] [Related]
6. Strategies in treating newly diagnosed or untreated multiple myeloma patients. From the Multiple Myeloma Research Foundation.
Weber DM
Oncology (Williston Park); 2003 Jun; 17(6):765-7. PubMed ID: 12846120
[TBL] [Abstract][Full Text] [Related]
7. Role of autologous stem-cell transplantation in multiple myeloma.
Attal M; Harousseau JL
Best Pract Res Clin Haematol; 2007 Dec; 20(4):747-59. PubMed ID: 18070717
[TBL] [Abstract][Full Text] [Related]
8. Supportive therapies in the management of myeloma.
Ludwig H;
Oncology (Williston Park); 2004 Mar; 18(3):295-6, 298. PubMed ID: 15065700
[No Abstract] [Full Text] [Related]
9. Treatment of multiple myeloma in the targeted therapy era.
Saad AA; Sharma M; Higa GM
Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
[TBL] [Abstract][Full Text] [Related]
10. Myeloma (multiple).
Kumar A; Djulbegovic B
Clin Evid; 2006 Jun; (15):1-29. PubMed ID: 16973003
[No Abstract] [Full Text] [Related]
11. Management of multiple myeloma: the changing landscape.
Reece DE
Blood Rev; 2007 Nov; 21(6):301-14. PubMed ID: 17761373
[TBL] [Abstract][Full Text] [Related]
12. Gastric relapse of plasma-cell myeloma after stem-cell transplantation.
Pollheimer VS; Pollheimer MJ; Eherer AJ; Langner C
Gastrointest Endosc; 2007 Jul; 66(1):179-80; discussion 180. PubMed ID: 17451699
[No Abstract] [Full Text] [Related]
13. Targeted treatments to improve stem cell outcome: old and new drugs.
Raab MS; Breitkreutz I; Anderson KC
Bone Marrow Transplant; 2007 Dec; 40(12):1129-37. PubMed ID: 17768392
[TBL] [Abstract][Full Text] [Related]
14. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma.
de Lavallade H; El-Cheikh J; Faucher C; Fürst S; Stoppa AM; Coso D; Bouabdallah R; Chabannon C; Gastaut JA; Blaise D; Mohty M
Bone Marrow Transplant; 2008 Jun; 41(11):953-60. PubMed ID: 18297115
[TBL] [Abstract][Full Text] [Related]
15. Single-centre experience with nonmyeloablative allogeneic stem cell transplantation in patients with multiple myeloma: prolonged remissions induced.
van Dorp S; Meijer E; van de Donk NW; Dekker AW; Nieuwenhuis K; Minnema MC; Petersen E; Schutgens R; Verdonck LF; Lokhorst HM
Neth J Med; 2007 May; 65(5):178-84. PubMed ID: 17519513
[TBL] [Abstract][Full Text] [Related]
16. Advances in therapy of multiple myeloma.
Bladé J; Rosiñol L
Curr Opin Oncol; 2008 Nov; 20(6):697-704. PubMed ID: 18841053
[TBL] [Abstract][Full Text] [Related]
17. Melphalan and dexamethasone for patients with multiple myeloma who are not candidates for autologous stem cell transplantation.
Sharma A; Lokeshwar N; Raina V; Mohanti BK; Kumar R
Natl Med J India; 2007; 20(3):121-4. PubMed ID: 17867615
[TBL] [Abstract][Full Text] [Related]
18. Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment.
Heider U; Kaiser M; Mieth M; Lamottke B; Rademacher J; Jakob C; Braendle E; Stover D; Sezer O
Eur J Haematol; 2009 Jan; 82(1):31-8. PubMed ID: 19067746
[TBL] [Abstract][Full Text] [Related]
19. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
[TBL] [Abstract][Full Text] [Related]
20. Reduced-toxicity conditioning with fludarabine and treosulfan prior to allogeneic stem cell transplantation in multiple myeloma.
Schmidt-Hieber M; Blau IW; Trenschel R; Andreesen R; Stuhler G; Einsele H; Kanz L; Keilholz U; Marinets O; Beelen DW; Fauser AA; Volin L; Ruutu T; Uharek L; Fietz T; Knauf W; Hopfenmüller W; Thiel E; Freund M; Casper J
Bone Marrow Transplant; 2007 Apr; 39(7):389-96. PubMed ID: 17310135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
